Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost

This Phase 2 study tests whether adding a stereotactic radiation boost (using a CyberKnife system) after standard chemoradiation helps patients with locally advanced, inoperable non-small cell lung cancer (NSCLC). The boost delivers a concentrated dose of radiation to residual tumor areas. **You may be eligible if...** - You are 18 or older - You have stage III NSCLC (cancer in the lung with nearby lymph node involvement but not spread to distant organs) that cannot be removed with surgery - You have already completed induction chemotherapy and received at least 40 Gy of radiation as part of the standard treatment - Remaining tumor areas after initial radiation are small enough (1–3 targets, each under 5 cm) to receive the CyberKnife boost **You may NOT be eligible if...** - Your tumor volumes are too large or too numerous for the CyberKnife boost - You are not able to complete the required radiation dose constraints for nearby organs Talk to your doctor to see if this trial is right for you.